Wet Age-related Macular Degeneration
Conditions
Interventions
Trade Name: Lidocaine Hydrochloride Injection BP 2% w/v.
Product Name: Lidocaine Hydrochloride Injection BP 2% w/v.
Pharmaceutical Form: Injection*
Trade Name: Minims Proxymetacaine hydrochloride 0.
Sponsors
Plymouth Hospitals NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participant is willing and able to give informed consent for participation in the study. Male or Female, aged 50 years or above. Patients receiving subsequent doses of Intra Vitreal Lucentis Injection with a primary diagnosis of wet age related macular degeneration Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Patients not consenting to be included in the study. Patients on pain medication. Patients undergoing other Intra Vitreal procedure. Patients undergoing Intra Vitreal injection of Ranibizumab for the first time. Patients allergic to any components of the drug used in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate the equivalence in effectiveness of topical Proxymetacaine (0.5%) alone as an anaesthetic for Intra vitreal Lucentis injection and to compare it with sub-conjunctival Lignocaine (2%) without adrenaline injection combined with Proxymetacaine using a numeric pain scale.;Secondary Objective: To evaluate the side effect profile of procedure related side effects with topical Proxymetacaine 0.5% and compares it with sub-conjunctival Lignocaine (2%) without adrenaline injection.;Primary end point(s): Primary outcome measures; numeric pain analogue scale test 0.25 hour after the injection and a telephone interview to administering the verbal numeric pain scale to assess overall comfort of the entire procedure. | — |
Countries
United Kingdom
Outcome results
None listed